Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study
2020 · Annals of Hematology · 25 citations
https://doi.org/10.1007/s00277-020-04234-9